Third antigen's a charm: Gilead pens deal with Merus for up to three trispecific antibodies
Gilead has enlisted Merus in a research deal to develop new trispecific antibodies that can harness the immune system to fight cancer.
Merus will receive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
